Compare AGEN & GORO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | GORO |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 212.0M |
| IPO Year | 1999 | 2010 |
| Metric | AGEN | GORO |
|---|---|---|
| Price | $3.93 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.50 | $1.63 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 91.80 |
| EPS | ★ N/A | N/A |
| Revenue | $42,877,086.00 | ★ $99,759,000.00 |
| Revenue This Year | $107.63 | $25.99 |
| Revenue Next Year | N/A | $5.78 |
| P/E Ratio | $8.89 | ★ N/A |
| Revenue Growth | ★ 89.95 | 51.78 |
| 52 Week Low | $2.63 | $0.35 |
| 52 Week High | $7.34 | $1.87 |
| Indicator | AGEN | GORO |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 66.52 |
| Support Level | $2.96 | $0.79 |
| Resistance Level | $4.58 | $1.75 |
| Average True Range (ATR) | 0.42 | 0.11 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 37.53 | 95.24 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.